UroGen Pharma Ltd. (URGN)

Market Cap	527.78M
Revenue (ttm)	90.40M
Net Income (ttm)	-126.87M
Shares Out	46.09M
EPS (ttm)	-2.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	557,761
Open	11.59
Previous Close	11.52
Day's Range	11.13 - 11.91
52-Week Range	9.03 - 20.70
Beta	1.12
Analysts	Strong Buy
Price Target	40.75 (+255.9%)
Earnings Date	Mar 10, 2025

About URGN

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate are UGN-102, UGN-103 which is in phase 3 of clinical trial for intravesical solution, and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of seve...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 4, 2017
• Employees: 235
• Stock Exchange: NASDAQ
• Ticker Symbol: URGN
• Website: https://www.urogen.com

Financial Performance

In 2024, UroGen Pharma's revenue was $90.40 million, an increase of 9.29% compared to the previous year's $82.71 million. Losses were -$126.87 million, 24.1% more than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for URGN stock is "Strong Buy." The 12-month stock price forecast is $40.75, which is an increase of 255.90% from the latest price.

Price Target

$40.75

(255.90% upside)

Analyst Consensus: Strong Buy